公开(公告)号：US20230348547A1

公开(公告)日：2023-11-02

申请号：US18087045

申请日：2022-12-22

申请人： Ambrx, Inc. ,  Elanco US Inc.

发明人： Anna-Maria A. HAYS PUTNAM ,  Nick KNUDSEN ,  Thea NORMAN ,  Alan KODER ,  Vadim KRAYNOV ,  Lillian SKIDMORE ,  Peter C. CANNING

IPC分类号： C07K14/535

CPC分类号： C07K14/535 ,  A61K38/193

摘要： Modified bovine G-CSF polypeptides and uses thereof are provided.

公开(公告)号：US20230340051A1

公开(公告)日：2023-10-26

申请号：US18102933

申请日：2023-01-30

申请人： Elanco US Inc. ,  Ambrx, Inc.

发明人： Peter Connor CANNING ,  Nickolas KNUDSEN ,  Md Harunur RASHID

IPC分类号： C07K14/535 ,  A61K47/60 ,  A61P37/04 ,  A61P31/04 ,  A61K38/19

CPC分类号： C07K14/535 ,  A61K47/60 ,  A61P37/04 ,  A61P31/04 ,  A61K38/193

摘要： The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF). The pG-CSF variants are useful in treating preventing or reducing the incidence of bacterial infections in swine. Methods of treating swine are disclosed.

公开(公告)号：US11542310B2

公开(公告)日：2023-01-03

申请号：US16165813

申请日：2018-10-19

申请人： Ambrx, Inc. ,  Elanco US Inc.

发明人： Anna-Maria A. Hays Putnam ,  Nick Knudsen ,  Thea Norman ,  Alan Koder ,  Vadim Kraynov ,  Lillian Skidmore ,  Peter C. Canning

IPC分类号： C07K14/535 ,  A61K38/19

摘要： Modified bovine G-CSF polypeptides and uses thereof are provided.

公开(公告)号：US11510993B2

公开(公告)日：2022-11-29

申请号：US15765515

申请日：2016-09-30

申请人： Merck Sharp & Dohme Corp. ,  Ambrx, Inc.

发明人： Philip E. Brandish ,  Robert M. Garbaccio ,  Jeffrey Kern ,  Linda Liang ,  Sanjiv Shah ,  Dennis Zaller ,  Andrew Beck ,  Dennis Gately ,  Nick Knudsen ,  Anthony Manibusan ,  Jianing Wang ,  Ying Sun

IPC分类号： A61K47/68 ,  C07K16/28 ,  A61K45/06

摘要： Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.

公开(公告)号：US11459392B2

公开(公告)日：2022-10-04

申请号：US16224346

申请日：2018-12-18

申请人： Ambrx, Inc.

发明人： Richard S Barnett ,  Nick Knudsen ,  Ying Sun ,  Sandra Biroc ,  Timothy Buss ,  Tsotne Javahishvili ,  Damien Bresson ,  Shailaja Srinagesh ,  Amha Hewet ,  Jason Pinkstaff

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61K47/42 ,  C07K5/062

摘要： This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

公开(公告)号：US11420999B2

公开(公告)日：2022-08-23

申请号：US17142169

申请日：2021-01-05

申请人： Ambrx, Inc.

发明人： Zhenwei Miao ,  Kyle Atkinson ,  Sandra Biroc ,  Timothy Buss ,  Melissa Neal ,  Vadim Kraynov ,  Robin Marsden ,  Jason Pinkstaff ,  Lillian Skidmore ,  Ying Sun ,  Agnieszka Szydlik ,  Delia Ianina Lopez De Valenta

IPC分类号： C07K5/10 ,  C07K5/103 ,  C07D207/08 ,  C07D401/12 ,  C07D417/12 ,  C07K5/02 ,  A61K47/68 ,  A61K38/07 ,  C07K5/062

摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

公开(公告)号：US20220257720A1

公开(公告)日：2022-08-18

申请号：US17685658

申请日：2022-03-03

申请人： AMBRX, INC.

发明人： Vadim KRAYNOV ,  Nick KNUDSEN ,  Amha HEWET ,  Kristine DE DIOS ,  Jason PINKSTAFF ,  Lorraine SULLIVAN

IPC分类号： A61K38/22 ,  C07K14/64

摘要： Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.

公开(公告)号：US20220226488A1

公开(公告)日：2022-07-21

申请号：US17429911

申请日：2020-02-12

申请人： Ambrx, Inc.

发明人： Sung-Ju MOON ,  Brian LEON ,  Mingchao KANG ,  Nickolas KNUDSEN ,  Jianing WANG ,  Sukumar SAKAMURI ,  Feng TIAN

IPC分类号： A61K47/68 ,  A61P37/04 ,  A61P35/00 ,  C07D471/04 ,  C07D471/14 ,  C07D473/18 ,  C07D473/34 ,  C07D487/04 ,  C07D487/14 ,  C07D519/00

摘要： Disclosed herein are Trastuzumab-linked TLR-agonist derivative analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The Trastuzumab-linked TLR-agonist derivative analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such Trastuzumab-linked TLR-agonist derivative analogs. Typically, the modified Trastuzumab-linked TLR-agonist derivative analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs and modified non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs, including therapeutic, diagnostic, and other biotechnology use.

公开(公告)号：US20220033518A1

公开(公告)日：2022-02-03

申请号：US17003952

申请日：2020-08-26

申请人： Ambrx,Inc.

发明人： Richard Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nickolas Knudsen ,  Andrew Beck ,  Ying Sun

IPC分类号： C07K16/40 ,  C07K16/30 ,  C07K5/02 ,  A61K47/68

摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

公开(公告)号：US20220009986A1

公开(公告)日：2022-01-13

申请号：US17285896

申请日：2019-10-19

申请人： Ambrx, Inc.

发明人： Mingchao Kang ,  Yingchun Lu ,  Nickolas Knudsen ,  MD Harunur Rashid ,  Feng Tian

IPC分类号： C07K14/54 ,  C07K19/00 ,  A61K45/06 ,  A61K47/65

摘要： The present invention provides methods for targeting interleukin-10 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-10 (IL-10) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-10 receptor.